Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda’s Half-Year Sales Slip on LLP Transfer, but Profits Zoom
Takeda Pharmaceutical saw its half-year revenue dip due to the stronger yen and divestitures including the transfer of long-listed products (LLPs) to a joint venture with Teva, but its profit grew strongly on the back of a one-time gain from…
To read the full story
Related Article
- Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
May 11, 2017
- Takeda Mum on Kaketsuken Biz Transfer; CEO Says He Needs to Better Understand Situation
November 1, 2016
- Takeda Ditches Flu Vaccine TAK-850 from Pipeline
October 31, 2016
- Takeda Enjoys Higher Revenues and Profits as Entyvio Sales Triple
May 11, 2016
- Entyvio’s Sales Jump Underpins Takeda’s Half-Year Revenue
November 2, 2015
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…